Personalis to Participate in Upcoming Investor Events

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the following investor events: Craig Hallum 23rd Annual Institutional Investor Conference on May 28, 2026 at the Depot Renaissance Hotel in Minneapolis, MN. Jefferies 2026 Global Healthcare Conference on June 3, 2026 at the Marriot Marquis in New York, NY. About Personalis, Inc. At Personalis, we are transformi.

Business Wire • May 14, 2026

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the company's NeXT Personal minimal residual disease (MRD) test to include immunotherapy monitoring for patients with late-stage solid tumors. This coverage determination is underpinned by landmark clinical evidence generated in.

Business Wire • May 13, 2026

Personalis Q1 Earnings Call Highlights

Personalis NASDAQ: PSNL reported first-quarter 2026 revenue of $15.5 million as management said the company is prioritizing growth in its clinical minimal residual disease, or MRD, testing business and biopharma MRD programs over lower-margin legacy enterprise revenue.

MarketBeat • May 8, 2026

Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript

Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

Personalis Reports First Quarter Results and Recent Highlights

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the first quarter ended March 31, 2026, highlighted recent business accomplishments, and reaffirmed financial guidance for the full year 2026. First Quarter and Recent Strategic and Operational Highlights Secured Milestone Medicare Coverage for Lung Cancer: Received Medicare coverage approval in the first quarter for the su.

Business Wire • May 7, 2026

Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates

Personalis (PSNL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.18 per share a year ago.

Zacks Investment Research • May 8, 2026

Personalis to Announce First Quarter 2026 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2026 financial results on Thursday, May 7, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domesti.

Business Wire • Apr 23, 2026

Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the successful presentation of clinical data at the American Association for Cancer Research (AACR) Annual Meeting. The data, spanning one oral podium presentation and three posters, underscore the use of the NeXT Personal ultrasensitive ctDNA assay in monitoring treatment response, identifying early recurrence, and tracking the emergence of therapy resistance.

Business Wire • Apr 21, 2026

Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that an oral podium presentation featuring colorectal cancer data for the company's NeXT Personal ultrasensitive ctDNA assay and three posters will be presented at the American Association for Cancer Research (AACR) Annual Meeting April 17-22, 2026, in San Diego, California. A focus of this year's data is the introduction of a new NeXT Personal MRD test option.

Business Wire • Apr 13, 2026

Personalis to Participate in the 25th Annual Needham Virtual Conference

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the 25th Annual Needham Virtual Conference on Wednesday, April 15, 2026. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our hig.

Business Wire • Apr 1, 2026